Pfizer (NYSE:PFE) Shares Up 1.7% Following Dividend Announcement

Key Points

• Pfizer shares rose 1.7% after the company announced a quarterly dividend of $0.43 per share, or $1.72 annualized, representing a yield of about 6.2%. The dividend is payable December 7 to shareholders of record November 6.
• Analyst sentiment remains cautious: Pfizer has an average rating of “Hold” and a consensus price target of $28.56, with five Buy, fourteen Hold, and two Sell ratings.
• Pfizer’s latest quarterly results exceeded expectations, with adjusted EPS of $0.77 versus the $0.68 consensus and revenue of $15.03 billion versus $14.40 billion expected. However, its dividend payout ratio stands at a high 226.32%, raising sustainability concerns.

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) traded up 1.7% during trading on Wednesday following a dividend announcement from the company. The company traded as high as $28.17 and last traded at $27.9640. Approximately 30,161,760 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 40,481,164 shares. The stock had previously closed at $27.50.The newly announced dividend which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer's dividend payout ratio (DPR) is 226.32%.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Wall Street Zen upgraded Pfizer from a "hold" rating to a "buy" rating in a research note on Sunday, September 13th. Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a report on Friday, July 10th. BMO Capital Markets lowered their price objective on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, July 13th. Royal Bank Of Canada upgraded Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. Finally, Guggenheim lowered their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a report on Friday, August 7th. Five analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $28.56.

Pfizer Stock Performance

The business's 50-day simple moving average is $27.50 and its two-hundred day simple moving average is $26.48. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The firm has a market cap of $159.39 billion, a price-to-earnings ratio of 36.80, a P/E/G ratio of 1.84 and a beta of 0.32.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the firm earned $0.78 EPS. The company's quarterly revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a first-line maintenance treatment for advanced HER2-positive breast cancer. The expanded indication could increase the drug’s addressable market and support Pfizer’s oncology portfolio. Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease
• Positive Sentiment: Phase 3 results for oral LITFULO showed meaningful facial and total-body repigmentation in patients with nonsegmental vitiligo, along with favorable tolerability. Pfizer plans regulatory submissions, potentially broadening the drug’s immunology opportunity. Pfizer Posted Positive Phase 3 Vitiligo Results for LITFULO
• Positive Sentiment: Pfizer declared a quarterly dividend of $0.43 per share, equal to $1.72 annually and a yield of approximately 6.3% based on the cited share price. The payout supports the stock’s appeal to income-focused investors. Pfizer Declares Fourth-Quarter 2026 Dividend
• Neutral Sentiment: Pfizer raised its 2026 revenue guidance while maintaining earnings guidance and announcing additional cost reductions. However, the second-quarter results included a $0.04 per-share loss, highlighting pressure on profitability despite the improved revenue outlook. Pfizer Trades Below Its Own Average Multiple
• Negative Sentiment: Pfizer will reportedly eliminate roughly 330 jobs at its Sicily plant in Italy. The cuts may reduce costs, but they also underscore ongoing restructuring and operational pressure. Pfizer to Cut Around 330 Jobs in Italy
• Negative Sentiment: Vaxcyte’s positive Phase 3 results for VAX-31 intensified concerns about competition to Pfizer’s major Prevnar franchise, which generated approximately $6.5 billion in revenue. A successful rival vaccine could pressure future sales and pricing. Pfizer’s Prevnar Franchise Faces a New Challenger
• Negative Sentiment: Recent coverage highlights concern that Pfizer’s dividend payout substantially exceeds reported earnings, raising questions about its long-term sustainability if profitability does not improve. Is Pfizer a Good or Bad Investment at Today’s Price?

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Angeles Wealth Management LLC grew its stake in Pfizer by 2.2% in the second quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company's stock worth $410,000 after purchasing an additional 358 shares during the period. Manchester Financial Inc. lifted its position in Pfizer by 2.9% during the second quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company's stock valued at $317,000 after buying an additional 365 shares during the period. Vermillion Wealth Management Inc. lifted its position in Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 382 shares during the period. Eagle Capital Management LLC boosted its holdings in shares of Pfizer by 0.3% during the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company's stock valued at $3,554,000 after buying an additional 390 shares in the last quarter. Finally, Delta Financial Advisors LLC boosted its holdings in shares of Pfizer by 1.6% during the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company's stock valued at $709,000 after buying an additional 398 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc NYSE: PFE is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company's portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.